CAJ | 학술논문

近年来甲状腺癌的发病率逐年升高，其中分化型甲状腺癌（DTC）占到了90%以上。一部分DTC可在自然状态下或治疗过程中失分化而发展为碘难治性分化型甲状腺癌（RAIR-DTC）。目前有关RAIR-DTC的定义尚未达成共识，这在一定程度上影响了其诊断与治疗。由于RAIR-DTC的治疗效果欠佳，一直是甲状腺癌的治疗难点。随着对甲状腺癌分子病理学研究的深入，分子靶向药物得到了迅速发展，尤其是其在碘难治性甲状腺癌中的应用取得了明显的效果，为甲状腺癌的治疗开辟了新的方向。
근년래갑상선암적발병솔축년승고，기중분화형갑상선암（DTC）점도료90%이상。일부분DTC가재자연상태하혹치료과정중실분화이발전위전난치성분화형갑상선암（RAIR-DTC）。목전유관RAIR-DTC적정의상미체성공식，저재일정정도상영향료기진단여치료。유우RAIR-DTC적치료효과흠가，일직시갑상선암적치료난점。수착대갑상선암분자병이학연구적심입，분자파향약물득도료신속발전，우기시기재전난치성갑상선암중적응용취득료명현적효과，위갑상선암적치료개벽료신적방향。
During the last few decades, the incidence of thyroid cancers has been escalating globally , with differentiated thyroid cancer ( DTC ) accounting for 90% of the cases . A portion of DTC dedifferentiates and becomes radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC), naturally or during cancer management. Currently, no consensus exists regarding the definition of RAIR-DTC, which to a certain extent influences its diagnosis and treatment. RAIR-DTC has always been a problem because its management lacks efficiency. As the understanding on the molecular pathophysiology of thyroid cancer continues to improve, targeted agents develop quickly, particularly in the treatment of RAIR-DTC, which will open up new directions for the management of thyroid cancer.